Camptosar irinotecan package insert
WebIn addition, homozygosity for *28 is specified as the primary risk factor in the Camptosar (irinotecan) package insert. 29 Consequently, we chose to limit the review of clinical validity to these ... http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Irinotecan_monograph.pdf
Camptosar irinotecan package insert
Did you know?
WebCamptosar (irinotecan) dosing, indications, interactions, adverse effects, and more Drugs & Diseases irinotecan (Rx) Brand and Other Names: Camptosar Classes: Antineoplastics, Topoisomerase... WebMay 11, 2024 · CAMPTOSAR is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. 2 DOSAGE AND ADMINISTRATION 2.1 Colorectal Cancer Combination Regimens 1 and 2 Administer CAMPTOSAR as a 90-minute intravenous infusion …
WebIrinotecan (Camptosar) patient drug information (UpToDate) History of changes in FDA indication 6/14/1996: Initial accelerated approval for the treatment of patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following 5 … WebCAMPTOSAR Injection (irinotecan hydrochloride injection) is an antineoplastic agent of the topoisomerase I inhibitor class. CAMPTOSAR is supplied as a sterile, pale yellow, clear, aqueous solution. Each... Read more Did you find an answer to your question? Yes No 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action
WebThe CAMPTOSAR (irinotecan) package insert recommends a reduced initial dose be considered for patients homozygous for the UGT1A1*28 allele and are at an increased risk for neutropenia following initiation of CAMPTOSAR treatment. AutoGenomics Doc EM-34028E (English) Rev. K (CO 4180A) Feb. 2024 WebApr 1, 2024 · US Brand Name Camptosar Novaplus Irinotecan Hydrochloride Descriptions Irinotecan injection is given together with other medicines (eg, 5-fluorouracil, leucovorin) to treat patients with metastatic cancer (a cancer that …
WebThe concentrate contains 20 mg/ml irinotecan hydrochloride trihydrate (equivalent to 17.33 mg/ml irinotecan). Excipients: sorbitol, lactic acid and water for injections. The pH of the solution is adjusted to 3.5 with sodium hydroxide. Vials of CAMPTO contain 40 mg or 100 mg or 300 mg of irinotecan hydrochloride trihydrate. THERAPEUTIC INDICATIONS
WebMay 11, 2024 · CAMPTOSAR is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. 2 DOSAGE AND ADMINISTRATION 2.1 Colorectal Cancer Combination Regimens 1 and 2. Administer CAMPTOSAR as a 90-minute intravenous infusion … son bayernWebTrade Name: CAMPTOSAR; CAMPTO Chemical Family: Mixture Intended Use: Pharmaceutical product used as Antineoplastic 2. HAZARDS IDENTIFICATION ... Irinotecan Hydrochloride 100286-90-6 Not Listed Mut. Cat.3;R68 Repr. Cat.3;R61 Xn;R22 2% Sodium hydroxide 1310-73-2 215-185-5 C;R35 ** son be a dentistWebSep 6, 2024 · CAMPTOSAR should be administered as an intravenous infusion over 90 minutes. CAMPTOSAR Injection must be diluted prior to infusion. CAMPTOSAR should be diluted in 5% Dextrose Injection, USP, (preferred) or 0.9% Sodium Chloride Injection, USP, to a final concentration range of 0.12 to 2.8 mg/mL. sonbeam daycareWebAug 1, 1998 · ABSTRACT: Irinotecan (CPT-11 [Camptosar]) is an important new chemotherapeutic drug that demonstrates activity against a broad spectrum of malignancies, including carcinomas of the colon, stomach, and lung. ... Pharmacia & Upjohn: Irinotecan Package Insert. 59. Goncalves E, de Costa L, Abigerges D, et al: A new enkephalinase … small delivery company los angelesWebIRINOTECAN Hydrochloride Injection, USP* Brand Name Equivalent: CAMPTOSAR®(CAMPTOSAR is a registered trademark of Yakult Honsha Company, Ltd.) Therapeutic Category: Antineoplastic Agent PreventIV Measures®Features: Easy-to-read drug name and dosage strength to aid in identifying the right product s on bbcWebMar 21, 2024 · Irinotecan (Camptosar ©, CPT-11), a topoisomerase I inhibitor, is a commonly used cytotoxic chemotherapeutic in the treatment of multiple malignancies, particularly of gastrointestinal origin. Dysarthria secondary to irinotecan has been described as a rare side effect in a few case reports with limited data to recommend appropriate … sonbeam daycare portlandWebcombination with leucovorin and oxaliplatin or irinotecan, is 400 mg/m. 2. by intravenous bolus on Day 1, followed by 2400 mg/m. to 3000 mg/m. 2. intravenously as a continuous infusion over 46 hours every two weeks. The recommended dose of fluorouracil, if administered in a bolus dosing regimen in combination with leucovorin, is 500 mg/m son be a good man song